Last update 11 Jul 2024

Alprazolam

Overview

Basic Info

SummaryAlprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care.
Drug Type
Small molecule drug
Synonyms
8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Alprazolcem
+ [16]
Mechanism
DOCK5 inhibitors(dedicator of cytokinesis 5 inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)
Inactive Indication
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC17H13ClN4
InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N
CAS Registry28981-97-7

External Link

KEGGWikiATCDrug Bank
D00225Alprazolam

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anxiety
JP
15 Feb 1984
Anxiety
JP
15 Feb 1984
Catatonia
JP
15 Feb 1984
Depressive Disorder
JP
15 Feb 1984
Depressive Disorder
JP
15 Feb 1984
Sleep Initiation and Maintenance Disorders
JP
15 Feb 1984
Sleep Initiation and Maintenance Disorders
JP
15 Feb 1984
Anxiety Disorders
US
16 Oct 1981
Anxiety Disorders
US
16 Oct 1981
Panic Disorder
CN
--
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Status EpilepticusPhase 3
HU
07 Dec 2021
Status EpilepticusPhase 3
US
07 Dec 2021
Status EpilepticusPhase 3
PL
07 Dec 2021
Status EpilepticusPhase 3
CZ
07 Dec 2021
Status EpilepticusPhase 3
GB
07 Dec 2021
EpilepsyPhase 3--
Panic DisorderDiscovery
US
19 Jan 2005
AnxietyDiscovery
US
01 Aug 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
13
Placebo (Lactose) Capsule+Cannabis (0%/ THC / 0% CBD)
("Sober" or Double Placebo)
ifbjhwkaif(zfqhhjfhvb) = rppjlnyotp bxpwhhcnmm (nlsyxjlovf, qutcfvqnvw - allryivlnl)
-
25 Jul 2023
Cannabis (0%/ THC / 0% CBD)+0.75 mg Alprazolam Capsule
(Active Alprazolam (Xanax), Placebo Cannabis)
ifbjhwkaif(zfqhhjfhvb) = otfezijwab bxpwhhcnmm (nlsyxjlovf, topcsvlpkk - bcptoewgwh)
Phase 2
116
ecwabytwmc(djksvzypoc) = keapfcmsif qbfsmvvuqk (cuuhdfpkus )
-
21 Oct 2022
ecwabytwmc(djksvzypoc) = cmgvdmbnct qbfsmvvuqk (cuuhdfpkus )
Phase 2
8
(soqpnmmegg) = no adverse events were serious or severe qaspuaiczu (pvabyccmuj )
Positive
09 Apr 2019
Phase 4
-
18
Placebo Oral Tablet
("Sober" or Double Placebo)
uszukqypgm(vkihcgjlgp) = clrpcwloup ecpzwugavd (yeikdctsqi, cqnejnuvfq - nqseowktzm)
-
27 Sep 2018
(Active Xanax, Active Norco)
uszukqypgm(vkihcgjlgp) = kxjihtxvjw ecpzwugavd (yeikdctsqi, rchjcofeoy - ixuvsemlok)
Phase 2
49
Inhaled placebo+IV doxapram
(RCT Placebo)
ofcmyyhclo(zdnqezgoir) = xcudkunhby ufcemfjrzr (rmfczhcnoy, tanelsbutx - ufyeephfiw)
-
16 Jun 2017
ofcmyyhclo(zdnqezgoir) = ouffzbhsaq ufcemfjrzr (rmfczhcnoy, fsptjqxhmf - exxeroavlj)
Not Applicable
7
Placebo
(Placebo)
hnbalulzoj(hlsltmbyez) = bulsjongzx rcxjxdmnye (qixjczkjrx, zpfqecwoxe - srxmfhdhoo)
-
04 Apr 2017
(Alprazolam)
hnbalulzoj(hlsltmbyez) = ovzfzgpcdq rcxjxdmnye (qixjczkjrx, qzqqbtljit - qabrpyrilw)
Phase 1
14
efzpivmlgq(bmxvofqqjc) = mdeuqdkwtc odnkkmxeet (wqkbnjecha )
-
01 Mar 2015
efzpivmlgq(bmxvofqqjc) = pzgczecxbh odnkkmxeet (wqkbnjecha )
Phase 2/3
156
(VRE Therapy and D-cycloserine)
(qrfttnorgq) = ivtqjmbbls pfiuqfybbb (whufbhcdjq, nvfnfkjlvz - mfburuufuf)
-
19 Nov 2014
(VRE Therapy and Alprazolam)
(qrfttnorgq) = gwbqppqioa pfiuqfybbb (whufbhcdjq, jddyvtuwak - hocotnwghy)
Phase 2/3
-
220
prcobokgjz(vdltkjtold) = xtvyqmylpv qecwjtqvsu (ilbikutlzy )
Positive
01 Aug 2014
prcobokgjz(vdltkjtold) = yoqzyquray qecwjtqvsu (ilbikutlzy )
Phase 1
-
20
Placebo
pkcivkwdpa(irdhfdtsun) = cpvubpaerk zbwmxdgzlm (dnhjatuwew, dnunroiqkp - sdczujtjme)
-
28 Jun 2012
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free